



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Minocycline hydrochloride

Chemical Properties

CAS No. :	13614-98-7
Formula:	C ₂₃ H ₂₈ ClN ₃ O ₇
Molecular Weight:	493.94
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Minocycline hydrochloride (Minocycline HCl) is a tetracycline antibiotic with excellent absorption and tissue penetration that is used for several bacterial infections as well as treatment of acne. Minocycline hydrochloride can cause both an acute hepatitis-like syndrome occurring within 1 to 3 months of starting therapy or a more insidious chronic hepatitis with autoimmune features typically after long-term treatment.
Targets(IC50)	HIF/HIF Prolyl-Hydroxylase,Antibacterial,Antibiotic
In vitro	Minocycline exhibits significant neuroprotective effects in models of cerebral ischemia, traumatic brain injury, Huntington's disease, and Parkinson's disease. Its neuroprotective properties may involve the inhibition of 5-lipoxygenase (an inflammatory enzyme associated with brain aging). Additionally, Minocycline's activity is linked to the inhibition of protein synthesis.
In vivo	Minocycline inhibits the release of cytochrome c mediated by the permeability transition in mitochondria. This inhibition by minocycline on cytochrome c release has been demonstrated in vivo, in cells, and isolated mitochondria. Additionally, minocycline suppresses the activity of inducible caspase-1 and caspase-3, inducible nitric oxide synthase (iNOS), and p38 mitogen-activated protein kinase (MAPK). Following experimental focal ischemia, minocycline reduces the upregulation of caspase-1 and iNOS, thereby decreasing infarct size.

Solubility Information

Solubility	H ₂ O: 12.4 mg/mL (25 mM), DMSO: 60 mg/mL (121.47 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0245 mL	10.1227 mL	20.2454 mL
5 mM	0.4049 mL	2.0245 mL	4.0491 mL
10 mM	0.2025 mL	1.0123 mL	2.0245 mL
50 mM	0.0405 mL	0.2025 mL	0.4049 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Wang X, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10483-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481